We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.36B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+42.81%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.08B
AUM Growth
+$85.4M
(+8.5%)
Cap. Flow
-$149M
Cap. Flow
% of AUM
-13.71%
Top 10 Holdings %
Top 10 Hldgs %
60.85%
Holding
62
New
9
Increased
7
Reduced
15
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$57.7M |
| 2 |
Xencor
XNCR
|
+$35.6M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$28.4M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$24M |
| 5 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$17.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KYNB
Kyntra Bio
KYNB
|
+$73.6M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$44.7M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$39.2M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$27.9M |
| 5 |
Assembly Biosciences
ASMB
|
+$26.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
ProQR Therapeutics
PRQR
$244M
| – | – |
-11,022
| Closed | -$174K |
|
|
SGMO
52
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-1,185,831
| Closed | -$13.6M |
|
53
Solid Biosciences
SLDB
$777M
| – | – |
-57,816
| Closed | -$23.2M |
|
54
Wave Life Sciences
WVE
$1.14B
| – | – |
-233,933
| Closed | -$9.84M |
|
55
Traws Pharma
TRAW
$7.92M
| – | – |
-1,129
| Closed | -$893K |
|
|
CNST
56
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-79,194
| Closed | -$318K |
|
|
FPRX
57
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-326,775
| Closed | -$3.04M |
|
|
AKCA
58
DELISTED
Akcea Therapeutics Inc
AKCA
| – | – |
-639,743
| Closed | -$19.3M |
|
|
PTLA
59
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-247,858
| Closed | -$4.84M |
|
|
ARRY
60
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-644,002
| Closed | -$9.18M |
|
|
CELG
61
CALL
DELISTED
Celgene Corp
CELG
| – | – |
-195,000
| Closed | -$12.5M |
|
|
IMDZ
62
DELISTED
Immune Design Corp.
IMDZ
| – | – |
-5,603,191
| Closed | -$7.28M |
|
Similar funds
HFM
CC
SCA
ROIC
BJL
G
MC
CIP
EcoR1 Capital's Q1 2019 Portfolio in Review
As of Q1 2019, EcoR1 Capital held 62 positions worth $1.08B, up 8.5% from $999M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
EcoR1 Capital withdrew a net $149M in Q1 2019, closing 21 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $39.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 78% a quarter earlier.
Against the trend, EcoR1 Capital opened a new position in Ultragenyx Pharmaceutical worth $34.5M.
- EcoR1 Capital's largest Q1 2019 buy was Ultragenyx Pharmaceutical: 497,899 shares worth $34.5M.
- EcoR1 Capital added most to CRISPR Therapeutics in Q1 2019, an estimated $57.7M increase.
- EcoR1 Capital's biggest Q1 2019 reduction was Kyntra Bio, cutting an estimated $73.6M.
- EcoR1 Capital fully exited Ionis Pharmaceuticals in Q1 2019, selling an estimated $39.2M.
- EcoR1 Capital's ten largest holdings make up 61% of its $1.08B portfolio in Q1 2019.
- EcoR1 Capital opened 9 new positions and closed 21 in Q1 2019.
- EcoR1 Capital's portfolio value rose 8.5% quarter-over-quarter to $1.08B.
Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.